

LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	JP 5-246885	09/24/93	JP-A Kokai		
	B02	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B03	WO 95/05465	02/23/95	Amgen, Inc.		
	B04	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd.		
	B05	WO 97/32895	12/12/97	Regents of the University of California		
	B06	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B07	WO 00/35475	06/22/00	Ehrenreich		
	B08	WO 01/82952	11/08/01	Action Pharma APS		
	B09	WO 01/82953	11/08/01	Action Pharma APS		
	B10	EP 555880	08/18/93	Bristol-Myers Squibb Company		
	B11	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B12	WO 96/14081	5/17/96	Boehringer Mannheim gmbh		
	B13	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C02	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C03	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C04	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	
	C05	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C06	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C07	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C08	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C09	BONDY, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease", Proc. Soc. Exp. Biol. Med. 208:337-345	

EXAMINER
 NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C10	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227:1385-1388.	
	C11	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97:10526-10531	
	C12	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81:1593-1597.	
	C13	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C14	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C15	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C16	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C17	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C18	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C19	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C20	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C21	DIPAULO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C22	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C23	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116:2293-2299.	
	C24	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-17521.	
	C25	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C26	Eur. Pharmacopoeia, 1997, p. 5.	
	C27	Eur. Pharmacopoeia, Suppl. 2001, pp. 777-782.	
	C28	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C29	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C30	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73:84-89.	
	C31	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C32	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249:4202-4206.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C33	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97:315-323.	
	C34	GOLDWASSER et al., "Erythropoietin: Assay and Study of Its Mode of Action," Hormone Assays, pp. 109-121.	
	C35	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99:9450-9455 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.142287899)	
	C36	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99:5627-5631	
	C37	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression", Blood 94:87-96	
	C38	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C39	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Erythropoietin, 149:516-527.	
	C40	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C41	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59:153-156	
	C42	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C43	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C44	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C45	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	C46	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99:10659-10664 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.152321399)	
	C47	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43:40-49	
	C48	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52:235-249	
	C49	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27:929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C50	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.	
	C51	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96:826-828.	
	C52	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C53	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	

EXAMINER

NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140
	APPLICANT Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C54	LATINI et al., 1998, "Comparative efficacy of a DA2/ α 2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31:601-608	
	C55	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40:376-380	
	C56	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85:785-794	
	C57	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C58	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108:449-454	
	C59	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272:32395-32400	
	C60	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C61	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C62	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C- γ 1", Kidney Intl. 53:1259-1268	
	C63	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C64	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C65	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C66	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C67	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269:19488-19493	
	C68	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268:11208-11216	
	C69	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C70	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	
	C71	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252:5558-5564.	
	C72	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243:155-159.	
	C73	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C74	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C75	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am.	

EXAMINER NYI-3972311v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10165-037-999	APPLICATION NO. 10/520,140
	APPLICANT Brines et al.	
	FILING DATE January 3, 2005	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		J. Med. Sci. 315:199-201	
	C76	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C77	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(suppl. 2):25-31	
	C78	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(suppl. 2):12-15	
	C79	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C80	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17:713-731	
	C81	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. 27:66-70	
	C82	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C83	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C84	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. 57:347-352	
	C85	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C86	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19:1023-1030	
	C87	SADAMATO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C88	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C89	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	
	C90	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74:103-109	
	C91	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	
	C92	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C93	SILVA et al., 1999, "Erythropoietin can induce the expression of bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274:22165-22169	
	C94	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98:4044-4049	
	C95	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C96	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C97	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc.	

EXAMINER NYI-3972311v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140
	APPLICANT Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647


NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C98	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C99	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C100	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and ERYthrocytosis," British J. Haematology, 113:49-51.	
	C101	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. 13:241-252	
	C102	WEILAND et al., "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," 1982, Blut, 44:173-175.	
	C103	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C104	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C105	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14:478-485	
	C106	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C107	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C108	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18(1):129-38	

EXAMINER NYI-3972311v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,377,513	03/22/83	Sugimoto et al.	
	A02	4,703,008	10/27/87	Lin	
	A03	4,806,524	02/21/89	Kawaguchi et al.	
	A04	4,835,260	05/30/89	Shoemaker	
	A05	5,457,089	10/10/95	Fibi et al.	
	A06	5,547,933	08/20/96	Lin	
	A07	5,571,787	11/05/96	O'Brien et al.	
	A08	5,614,184	03/25/97	Sytkowski et al.	
	A09	5,618,698	04/08/97	Lin	
	A10	5,621,080	04/15/97	Lin	
	A11	5,625,035	04/29/97	Clemons	
	A12	5,661,125	08/26/97	Strickland	
	A13	5,696,080	12/09/97	O' Brien	
	A14	5,700,909	12/23/97	O'Brien	
	A15	5,714,459	02/03/98	O'Brien	
	A16	5,756,349	05/26/98	Lin	
	A17	5,767,078	06/16/98	Johnson et al.	
	A18	5,773,569	06/30/98	Wrighton et al.	
	A19	5,830,851	11/03/98	Wrighton et al.	
	A20	5,835,382	11/10/98	Wilson et al.	
	A21	5,856,298	01/05/99	Strickland	
	A22	5,888,772	03/30/99	Okasinski et al.	
	A23	5,955,422	09/21/99	Lin	
	A24	6,165,783	12/26/00	Weiss et al.	
	A25	4,658,019	04/14/87	Kung et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	JP 5-246885	09/24/93	JP-A Kokai		
	B02	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B03	WO 95/05465	02/23/95	Amgen, Inc.		
	B04	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd.		
	B05	WO 97/32895	12/12/97	Regents of the University of California		
	B06	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B07	WO 00/35475	06/22/00	Ehrenreich		
	B08	WO 01/82952	11/08/01	Action Pharma APS		
	B09	WO 01/82953	11/08/01	Action Pharma APS		
	B10	EP 555880	08/18/93	Bristol-Myers Squibb Company		
	B11	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B12	WO 96/14081	5/17/96	Boehringer Mannheim gmbh		
	B13	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C02	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C03	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C04	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	
	C05	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C06	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C07	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C08	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C09	BONDY, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease", Proc. Soc. Exp. Biol. Med. 208:337-345	

EXAMINER
NYI-3972311v2**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140 (National Stage of PCT/US2003/021350)
	APPLICANT Brines et al.	
	FILING DATE January 3, 2005	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C10	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227:1385-1388.	
	C11	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97:10526-10531	
	C12	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81:1593-1597.	
	C13	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C14	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C15	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C16	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C17	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C18	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C19	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C20	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C21	DIPAULO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C22	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C23	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116:2293-2299.	
	C24	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-17521.	
	C25	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C26	Eur. Pharmacopoeia, 1997, p. 5.	
	C27	Eur. Pharmacopoeia, Suppl. 2001, pp. 777-782.	
	C28	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C29	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C30	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73:84-89.	
	C31	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C32	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249:4202-4206.	
	C33	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97:315-323.	
	C34	GOLDWASSER et al., "Erythropoietin: Assay and Study of Its Mode of Action," Hormone Assays, pp. 109-121.	
	C35	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99:9450-9455 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.142287899)	
	C36	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99:5627-5631	
	C37	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression", Blood 94:87-96	
	C38	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C39	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Erythropoietin, 149:516-527.	
	C40	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C41	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59:153-156	
	C42	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C43	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C44	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C45	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	C46	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99:10659-10664 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.152321399)	
	C47	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43:40-49	
	C48	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52:235-249	
	C49	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27:929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C50	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140 (National Stage of PCT/US2003/021350)
	APPLICANT Brines et al.	
	FILING DATE January 3, 2005	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C51	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96:826-828.	
	C52	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C53	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C54	LATINI et al., 1998, "Comparative efficacy of a DA2/ α 2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31:601-608	
	C55	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40:376-380	
	C56	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85:785-794	
	C57	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C58	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108:449-454	
	C59	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272:32395-32400	
	C60	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C61	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C62	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C- γ 1", Kidney Intl. 53:1259-1268	
	C63	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C64	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C65	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C66	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C67	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269:19488-19493	
	C68	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268:11208-11216	
	C69	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C70	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	

EXAMINER NYI-3972311v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C71	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252:5558-5564.	
	C72	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243:155-159.	
	C73	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C74	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C75	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315:199-201	
	C76	NISSENSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C77	NISSENSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(suppl. 2):25-31	
	C78	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(suppl. 2):12-15	
	C79	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C80	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17:713-731	
	C81	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. 27:66-70	
	C82	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C83	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C84	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. 57:347-352	
	C85	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C86	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19:1023-1030	
	C87	SADAMATO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C88	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C89	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	
	C90	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74:103-109	
	C91	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C92	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C93	SILVA et al., 1999, "Erythropoietin can induce the expression of bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274:22165-22169	
	C94	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98:4044-4049	
	C95	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C96	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C97	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C98	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C99	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C100	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C101	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. 13:241-252	
	C102	WEILAND et al., "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," 1982, Blut, 44:173-175.	
	C103	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C104	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C105	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14:478-485	
	C106	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C107	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C108	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18(1):129-38	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,377,513	03/22/83	Sugimoto et al.	
	A02	4,703,008	10/27/87	Lin	
	A03	4,806,524	02/21/89	Kawaguchi et al.	
	A04	4,835,260	05/30/89	Shoemaker	
	A05	5,457,089	10/10/95	Fibi et al.	
	A06	5,547,933	08/20/96	Lin	
	A07	5,571,787	11/05/96	O'Brien et al.	
	A08	5,614,184	03/25/97	Sytkowski et al.	
	A09	5,618,698	04/08/97	Lin	
	A10	5,621,080	04/15/97	Lin	
	A11	5,625,035	04/29/97	Clemons	
	A12	5,661,125	08/26/97	Strickland	
	A13	5,696,080	12/09/97	O'Brien	
	A14	5,700,909	12/23/97	O'Brien	
	A15	5,714,459	02/03/98	O'Brien	
	A16	5,756,349	05/26/98	Lin	
	A17	5,767,078	06/16/98	Johnson et al.	
	A18	5,773,569	06/30/98	Wrighton et al.	
	A19	5,830,851	11/03/98	Wrighton et al.	
	A20	5,835,382	11/10/98	Wilson et al.	
	A21	5,856,298	01/05/99	Strickland	
	A22	5,888,772	03/30/99	Okasinski et al.	
	A23	5,955,422	09/21/99	Lin	
	A24	6,165,783	12/26/00	Weiss et al.	
	A25	4,658,019	04/14/87	Kung et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER

NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	JP 5-246885	09/24/93	JP-A Kokai		
	B02	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B03	WO 95/05465	02/23/95	Amgen, Inc.		
	B04	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd.		
	B05	WO 97/32895	12/12/97	Regents of the University of California		
	B06	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B07	WO 00/35475	06/22/00	Ehrenreich		
	B08	WO 01/82952	11/08/01	Action Pharma APS		
	B09	WO 01/82953	11/08/01	Action Pharma APS		
	B10	EP 555880	08/18/93	Bristol-Myers Squibb Company		
	B11	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B12	WO 96/14081	5/17/96	Boehringer Mannheim gmbh		
	B13	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C02	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C03	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C04	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	
	C05	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C06	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C07	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C08	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C09	BONDY, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease", Proc. Soc. Exp. Biol. Med. 208:337-345	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C10	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227:1385-1388.	
	C11	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97:10526-10531	
	C12	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81:1593-1597.	
	C13	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C14	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C15	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C16	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C17	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C18	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C19	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C20	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C21	DIPAULO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C22	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C23	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116:2293-2299.	
	C24	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-17521.	
	C25	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C26	Eur. Pharmacopoeia, 1997, p. 5.	
	C27	Eur. Pharmacopoeia, Suppl. 2001, pp. 777-782.	
	C28	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C29	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C30	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73:84-89.	
	C31	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140 (National Stage of PCT/US2003/021350)
	APPLICANT Brines et al.	
	FILING DATE January 3, 2005	ART UNIT 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C32	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249:4202-4206.	
	C33	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97:315-323.	
	C34	GOLDWASSER et al., "Erythropoietin: Assay and Study of Its Mode of Action," Hormone Assays, pp. 109-121.	
	C35	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99:9450-9455 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.142287899)	
	C36	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99:5627-5631	
	C37	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression", Blood 94:87-96	
	C38	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C39	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Erythropoietin, 149:516-527.	
	C40	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C41	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59:153-156	
	C42	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C43	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C44	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C45	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	C46	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99:10659-10664 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.152321399)	
	C47	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43:40-49	
	C48	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52:235-249	
	C49	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27:929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C50	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C51	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96:826-828.	
	C52	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C53	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C54	LATINI et al., 1998, "Comparative efficacy of a DA2/α2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31:601-608	
	C55	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40:376-380	
	C56	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85:785-794	
	C57	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C58	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108:449-454	
	C59	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272:32395-32400	
	C60	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C61	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C62	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-γ1", Kidney Intl. 53:1259-1268	
	C63	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C64	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C65	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C66	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C67	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269:19488-19493	
	C68	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268:11208-11216	
	C69	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C70	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C71	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252:5558-5564.	
	C72	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243:155-159.	
	C73	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C74	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C75	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315:199-201	
	C76	NISSONSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C77	NISSONSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(suppl. 2):25-31	
	C78	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(suppl. 2):12-15	
	C79	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C80	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17:713-731	
	C81	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. 27:66-70	
	C82	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups", J. Biol. Chem. 246(4):939-45	
	C83	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C84	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. 57:347-352	
	C85	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C86	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19:1023-1030	
	C87	SADAMATO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C88	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C89	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	
	C90	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74:103-109	
	C91	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C92	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C93	SILVA et al., 1999, "Erythropoietin can induce the expression of bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274:22165-22169	
	C94	SIREN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98:4044-4049	
	C95	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C96	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C97	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C98	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C99	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C100	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C101	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. 13:241-252	
	C102	WEILAND et al., "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," 1982, Blut, 44:173-175.	
	C103	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C104	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C105	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14:478-485	
	C106	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C107	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C108	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18(1):129-38	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	4,377,513	03/22/83	Sugimoto et al.	
	A02	4,703,008	10/27/87	Lin	
	A03	4,806,524	02/21/89	Kawaguchi et al.	
	A04	4,835,260	05/30/89	Shoemaker	
	A05	5,457,089	10/10/95	Fibi et al.	
	A06	5,547,933	08/20/96	Lin	
	A07	5,571,787	11/05/96	O'Brien et al.	
	A08	5,614,184	03/25/97	Sytkowski et al.	
	A09	5,618,698	04/08/97	Lin	
	A10	5,621,080	04/15/97	Lin	
	A11	5,625,035	04/29/97	Clemons	
	A12	5,661,125	08/26/97	Strickland	
	A13	5,696,080	12/09/97	O' Brien	
	A14	5,700,909	12/23/97	O'Brien	
	A15	5,714,459	02/03/98	O'Brien	
	A16	5,756,349	05/26/98	Lin	
	A17	5,767,078	06/16/98	Johnson et al.	
	A18	5,773,569	06/30/98	Wrighton et al.	
	A19	5,830,851	11/03/98	Wrighton et al.	
	A20	5,835,382	11/10/98	Wilson et al.	
	A21	5,856,298	01/05/99	Strickland	
	A22	5,888,772	03/30/99	Okasinski et al.	
	A23	5,955,422	09/21/99	Lin	
	A24	6,165,783	12/26/00	Weiss et al.	
	A25	4,658,019	04/14/87	Kung et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	JP 5-246885	09/24/93	JP-A Kokai		
	B02	WO 94/24160	10/27/94	Brigham and Women's Hospital		
	B03	WO 95/05465	02/23/95	Amgen, Inc.		
	B04	WO 97/18318	05/22/97	Takara Shuzo Co., Ltd.		
	B05	WO 97/32895	12/12/97	Regents of the University of California		
	B06	WO 98/18926	05/07/98	G.D. Searle & Co.		
	B07	WO 00/35475	06/22/00	Ehrenreich		
	B08	WO 01/82952	11/08/01	Action Pharma APS		
	B09	WO 01/82953	11/08/01	Action Pharma APS		
	B10	EP 555880	08/18/93	Bristol-Myers Squibb Company		
	B11	WO 92/08493	5/29/92	Brigham & Women's Hospital		
	B12	WO 96/14081	5/17/96	Boehringer Mannheim gmbh		
	B13	WO 02/10743	2/07/02	Ortho-McNeil Pharmaceutical, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C02	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C03	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. mond. Sante, 47:99-112.	
	C04	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	
	C05	BAUER, 1995, "The Oxygen Sensor That Controls EPO Production: Facts and Fancies," J. Perinat. Med., 23:7-12.	
	C06	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta", Biol. Reproduct. 60:861-870	
	C07	BERNAUDIN et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651	
	C08	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain", Glia 30:271-278	
	C09	BONDY, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease", Proc. Soc. Exp. Biol. Med. 208:337-345	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140 (National Stage of PCT/US2003/021350)
	APPLICANT	
	Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C10	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," Am. J. Physiol., 227:1385-1388.	
	C11	BRINES et al., 2000, "Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97:10526-10531	
	C12	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," Blood, 81:1593-1597.	
	C13	CAMISCOLI et al., 1968, "Comparative Assay of Erythropoietin Standards," Annals New York Acad. Sci., 149:40-45.	
	C14	CAMPANA et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241	
	C15	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," Arch. Phys. Med. Rehabil., 65:370-374.	
	C16	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, Annals New York Acad. Sci., 149:12-17.	
	C17	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," Nature, 191:1065-1067.	
	C18	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," Bull. Org. mond. Sante, 35:751-760.	
	C19	DIAZ-BRINTON et al., 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," Pharm. Res. 15(3):386-98	
	C20	DIGICAYLIOGLU et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA 92:3717-3720	
	C21	DIPAULO et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. 38:M477-M480	
	C22	DONG et al., 1992, "Receptor binding of asialoerythropoietin," J. Cell. Biochem. 48(3):269-76	
	C23	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," Endocrinol., 116:2293-2299.	
	C24	DUBE et al, 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," J. Biol. Chem., 263:17516-17521.	
	C25	EHRENREICH et al., 2002, "Erythropoietin therapy for acute stroke is both safe and beneficial", Molec. Med. 8(8):495-505	
	C26	Eur. Pharmacopoeia, 1997, p. 5.	
	C27	Eur. Pharmacopoeia, Suppl. 2001, pp. 777-782.	
	C28	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", Blood 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C29	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," Curr. Opin. Neurol. 15(4):483-9	
	C30	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," Blood, 73:84-89.	
	C31	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C32	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, J. Biol. Chem., 249:4202-4206.	
	C33	GOLDWASSER et al., 1975, "An Assay for Erythropoietin in Vitro at the Milliunit Level," Endo., 97:315-323.	
	C34	GOLDWASSER et al., "Erythropoietin: Assay and Study of Its Mode of Action," Hormone Assays, pp. 109-121.	
	C35	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma", Proc. Natl. Acad. Sci. USA 99:9450-9455 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.142287899)	
	C36	GRASSO et al., 2002, "Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage", Proc. Natl. Acad. Sci. USA 99:5627-5631	
	C37	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression", Blood 94:87-96	
	C38	GRIMM et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. 38:480-486	
	C39	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," Erythropoietin, 149:516-527.	
	C40	HEFTI, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. 37:239-267	
	C41	HENGEMIHLE et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. 59:153-156	
	C42	HIRAKATA et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. 262:F737-F743	
	C43	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," Neurology, 41:753-754.	
	C44	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," Eur. J. Biochem., 194:457-462.	
	C45	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7(13):1555-66	
	C46	JUNK et al., 2002, "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", Proc. Natl. Acad. Sci. USA 99:10659-10664 (PNAS Early Edition www.pnas.org/cgi/doi/10.1073/pnas.152321399)	
	C47	JUUL et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. 43:40-49	
	C48	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus", Early Human Devel. 52:235-249	
	C49	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep", Soc. for Neuroscience Abstracts 27:929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C50	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," Annals New York Acad. Sci., 149:18-24.	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C51	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," Obstetrics and Gynecology, 96:826-828.	
	C52	KONISHI et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. 609:29-35	
	C53	KOPF et al., 1994, "Memory improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. 62:237-243	
	C54	LATINI et al., 1998, "Comparative efficacy of a DA2/ α 2 agonist and a β blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. 31:601-608	
	C55	LI et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", Pediatr. Res. 40:376-380	
	C56	LI et al., 1998, "A single pre training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. 85:785-794	
	C57	LIPINSKI et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. 692:143-153	
	C58	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression", Proc. Assoc. Am. Physicians 108:449-454	
	C59	LIU et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. 272:32395-32400	
	C60	LIU et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. 166:159-169	
	C61	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," Nature, 185:102-103.	
	C62	MARRERO et al., 1998, "Erythropoietin receptor-operated Ca ²⁺ channels: activation by phospholipase C- γ 1", Kidney Intl. 53:1259-1268	
	C64	MARSH et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. 39:155-163	
	C64	MARTI et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. 51:416-418	
	C65	MARTI et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. 8:666-676	
	C66	MASUDA et al., 1997, "Insulin like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. 746:63-70	
	C67	MASUDA et al., 1994, "A novel site of erythropoietin production. Oxygen dependent production in cultured rat astrocytes", J. Biol. Chem. 269:19488-19493	
	C68	MASUDA et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. 268:11208-11216	
	C69	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," J. Surg. Oncology, 75:197-202.	
	C70	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells", Acta Endocrinologica 127:459-465	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140 (National Stage of PCT/US2003/021350)
	APPLICANT	
	Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C71	MIYAKE et al., 1977, "Purification of Human Erythropoietin," J. Biol. Chem., 252:5558-5564.	
	C72	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo, J. Biol. Chem., 243:155-159.	
	C73	MORISHITA et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate induced neuronal death", Neurosci. 76:105-116	
	C74	MOSS et al., 1996, "Oxygen administration enhances memory formation in healthy young adults", Psychopharmacol. 124:255-260	
	C75	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", Am. J. Med. Sci. 315:199-201	
	C76	NISSONSON et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", Ann. Int. Med. 114:402-416	
	C77	NISSONSON, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", Sem. Nephrol. 9(suppl. 2):25-31	
	C78	OGDEN, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", Sem. Nephrol. 9(suppl. 2):12-15	
	C79	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", Digestion 57:328-332	
	C80	PARDRIDGE, 1997, "Drug delivery to the brain", J. Cerebral Blood Flow Metab. 17:713-731	
	C81	PARDRIDGE et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo", J. Pharmacol. Exp. Ther. 27:66-70	
	C82	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," J. Biol. Chem. 246(4):939-45	
	C83	PODUSLO et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", Proc. Natl. Acad. Sci. USA 91:5705-5709	
	C84	PRENDERGAST et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", Pharmacol. Biochem. Behav. 57:347-352	
	C85	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," J. Biol. Chem. 250(18):7435-42	
	C86	ROSE et al., 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", Peptides 19:1023-1030	
	C87	SADAMATO et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", Biochem. Biophys. Res. Comm. 253:26-32	
	C88	SAKANAKA et al., 1998, "In vivo evidence that erythropoietin protects neurons from ischemic damage", Proc. Natl. Acad. Sci. USA 95:4635-4640	
	C89	SATAKE et al. 1990, "Chemical modification of erythropoietin: an increase in in vitro activity by guanidination," Biochim. Biophys. Acta. 1038(1):125-9	
	C90	SAWYER et al., 1989, "Receptors for erythropoietin in mouse and human erythroid cells and placenta", Blood 74:103-109	
	C91	SHIRAMIZU et al., 1994, "Constitutive Secretion of Erythropoietin by Human Renal Adenocarcinoma Cells in Vivo and in Vitro," Exp. Cell Res., 215:249-256.	

EXAMINER NYI-3972311v2	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-037-999

APPLICATION NO.

10/520,140
(National Stage of
PCT/US2003/021350)

APPLICANT

Brines et al.

FILING DATE

January 3, 2005

ART UNIT

1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C92	SHORE et al., 1968, "Quantitative Estimation of Erythropoietin," Annals New York Acad. Sci., 149:46-48.	
	C93	SILVA et al., 1999, "Erythropoietin can induce the expression of bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines", J. Biol. Chem. 274:22165-22169	
	C94	SIRÉN et al., 2001, "Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress", Proc. Natl. Acad. Sci. USA 98:4044-4049	
	C95	SPIVAK et al., 1989, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 73:90-99.	
	C96	STARK et al., 1960, "Reactions of the Cyanate Present in Aqueous Urea With Amino Acids and Proteins," J. Biol. Chem. 235(11): 3177-3181	
	C97	STEECE-COLLIER et al., 2002, "Etiology of Parkinson's disease: Genetics and environment revisited," Proc. Natl. Acad. Sci. U. S. A. 99(22):13972-4	
	C98	STORRING et al., 1998, "Epoietin Alfa and Beta Differ In Erythropoietin Isoform Compositions and Biological Properties," British J. Haematology, 100:79-89.	
	C99	STORRING et al., 1992, "The International Standard for Recombinant DNA-Derived Erythropoietin: Collaborative Study of Four Recombinant DNA-derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins," J. Endocrinol., 134:459-484.	
	C100	SUZUKI et al., 2001, "Erythropoietin Synthesis by Tumour Tissues in a Patient With Uterine Myoma and Erythrocytosis," British J. Haematology, 113:49-51.	
	C101	TABIRA et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro", Int. J. Devl. Neurosci. 13:241-252	
	C102	WEILAND et al., "In vivo Activity of Asialo-Erythropoietin in Combination with Asialo-Glycoproteins," 1982, Blut, 44:173-175.	
	C103	WESTENFELDER et al., 1999, "Human, rat and mouse kidney cells express functional erythropoietin receptors", Kidney Intl. 55:808-820	
	C104	WILLIAMS et al., 1994, "Human erythropoietin receptor", Ann. NY Acad. Sci. 718:232-244	
	C105	WOLCOTT et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", Am. J. Kidney Dis. 14:478-485	
	C106	WU et al., 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", PNAS 96:254-259	
	C107	YAMAJI et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", Eur. J. Biochem. 239:494-500	
	C108	YANG et al., 2002, "Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms," Biotechnol. Prog. 18(1):129-38	

EXAMINER
NYI-3972311v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.